FR2374910B1 - - Google Patents

Info

Publication number
FR2374910B1
FR2374910B1 FR7731603A FR7731603A FR2374910B1 FR 2374910 B1 FR2374910 B1 FR 2374910B1 FR 7731603 A FR7731603 A FR 7731603A FR 7731603 A FR7731603 A FR 7731603A FR 2374910 B1 FR2374910 B1 FR 2374910B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7731603A
Other versions
FR2374910A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Choay SA
Original Assignee
Choay SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB44132/76A external-priority patent/GB1591306A/en
Application filed by Choay SA filed Critical Choay SA
Publication of FR2374910A1 publication Critical patent/FR2374910A1/fr
Application granted granted Critical
Publication of FR2374910B1 publication Critical patent/FR2374910B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
FR7731603A 1976-10-23 1977-10-20 Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations Granted FR2374910A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB44132/76A GB1591306A (en) 1976-10-23 1976-10-23 Liposomes containing heparin and a process for obtaining them
GB3441077 1977-08-16

Publications (2)

Publication Number Publication Date
FR2374910A1 FR2374910A1 (fr) 1978-07-21
FR2374910B1 true FR2374910B1 (fr) 1981-07-10

Family

ID=26262280

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7731603A Granted FR2374910A1 (fr) 1976-10-23 1977-10-20 Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations

Country Status (14)

Country Link
US (1) US4239754A (fr)
JP (1) JPS6055485B2 (fr)
AR (1) AR224100A1 (fr)
AU (1) AU519231B2 (fr)
DD (1) DD138881A5 (fr)
DE (1) DE2747378A1 (fr)
DK (1) DK470277A (fr)
ES (1) ES463427A1 (fr)
FR (1) FR2374910A1 (fr)
IE (1) IE45894B1 (fr)
LU (1) LU78361A1 (fr)
NL (1) NL7711610A (fr)
PL (1) PL201666A1 (fr)
SE (1) SE7711895L (fr)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK22879A (da) * 1978-01-27 1979-07-28 Sandoz Ag Fremgangsmaade til fremstilling af et medikamentafgivelsessystem
GB2026340B (en) * 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
JPS56120612A (en) * 1980-02-27 1981-09-22 Kanebo Keshohin Kk Beautifying cosmetic
US4820811A (en) * 1982-04-21 1989-04-11 Research Corporation Amine reacted therapeutic agents
US4451647A (en) * 1982-06-21 1984-05-29 Research Corporation Heparinized polyorganophosphazenes
US4542019A (en) * 1983-03-11 1985-09-17 John Lezdey Antacid compositions
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
FR2568774B2 (fr) * 1984-05-30 1989-05-19 Choay Sa Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
US4923854A (en) * 1986-01-22 1990-05-08 The Liposome Company, Inc. Solubilization of hydrophobic materials using lysophospholipid
DE3614657A1 (de) * 1986-04-30 1987-11-05 Dornier Medizintechnik Pharmaka enthaltende lipidvesikel, verfahren zu ihrer herstellung und einbringung in den koerper eines lebewesens und freisetzung der in den lipidvesikeln enthaltende pharmaka
US4745107A (en) * 1986-08-20 1988-05-17 Foley Kevin M Heparin derivatives with improved permeability
US4745105A (en) * 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5008242A (en) * 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US4879282A (en) * 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
US4938965A (en) * 1987-07-22 1990-07-03 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Ocular delivery of prophylactic agents
US5733892A (en) * 1990-07-24 1998-03-31 Seikagaku Corporation Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same
EP0493622B1 (fr) * 1990-07-24 1997-02-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Glycosaminoglycane se combinant a un phospholipide ou a un lipide, production de ce compose et inhibiteur de metastase du cancer
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
AR244546A1 (es) * 1990-10-30 1993-11-30 Gador Y Cia S A C I Lab Dr Procedimiento para la preparacion de liposomas de drogas insolubles en aceite en capsulas blandas de gelatina enterosolubles.
JP3199405B2 (ja) * 1991-08-30 2001-08-20 生化学工業株式会社 肝細胞球状集塊化剤及び球状集塊化肝細胞の製造方法
FR2685868B1 (fr) * 1992-01-03 1995-06-23 Corbiere Jerome Nouvelles preparations pharmaceutiques a base de peptides pour la voie generale.
WO1995001163A1 (fr) * 1992-01-03 1995-01-12 Corbiere Jerome Nouvelles preparations pharmaceutiques a base de peptides pour la voie generale
US6916489B2 (en) * 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US5342621A (en) * 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US20010003001A1 (en) 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE4313402A1 (de) * 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermale Wirkstoffzubereitung
WO1994026251A1 (fr) * 1993-05-07 1994-11-24 Sequus Pharmaceuticals, Inc. Procede d'apport sous-cutane de liposomes
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
GB2320248B (en) * 1995-09-11 1999-04-14 Emisphere Tech Inc Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
AU3828597A (en) 1996-06-14 1998-01-07 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
IE960485A1 (en) * 1996-07-02 1998-01-14 Univ Dublin Organised assemblies containing entrapped negatively charged¹polyelectrolytes
WO1998021951A1 (fr) 1996-11-18 1998-05-28 Emisphere Technologies, Inc. Procede et composition pour induire une tolerance orale chez les mammiferes
CA2319672C (fr) 1997-02-07 2011-01-04 Emisphere Technologies, Inc. Composes et compositions destines a l'administration d'agents actifs
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) * 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
AU2845599A (en) * 1998-03-05 1999-09-20 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use
KR100314496B1 (ko) 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
CA2369591C (fr) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Sels disodiques, monohydrate, et solvates d'ethanol
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US7671029B2 (en) * 1999-08-06 2010-03-02 Immupharma Sa Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
US6908900B2 (en) * 2001-01-17 2005-06-21 Zimmer & Associates Ag Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7129274B1 (en) * 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
AU2274201A (en) 1999-12-16 2001-06-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP1423081A4 (fr) * 2001-06-25 2005-05-25 Depuy Int Ltd Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques
JP2004535434A (ja) * 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
WO2003020321A2 (fr) * 2001-09-06 2003-03-13 Zimmer Robert H Derives de pseudo-peptides, leur preparation et leurs utilisations biologiques
EP2308888B1 (fr) 2001-11-14 2017-03-01 Janssen Biotech, Inc. Anticorps anti-IL-6, compositions, méthodes et utilisations associées
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US20040072796A1 (en) * 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
WO2004002417A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
US6702850B1 (en) 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
EP1565167B1 (fr) * 2002-11-07 2016-06-22 Advanced Bionutrition Corporation Nutraceutiques et procede d'alimentation d'animaux aquatiques
AU2004239288B2 (en) 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
CN100398536C (zh) * 2003-08-20 2008-07-02 爱密斯菲尔科技公司 用于口服传递glp-1化合物或mc4激动剂肽的化合物、方法和制剂
ES2278346T3 (es) * 2003-08-20 2007-08-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para suministro oral de un compuesto peptido (glp)-1 del tipo de glucagon o un peptido agonista (glp)-4 del receptor 4 de melacortina (mc4).
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
JP2005209106A (ja) * 2004-01-26 2005-08-04 Nec Corp 携帯通信端末、受信メール管理方法、プログラムおよび記録媒体
US7252446B2 (en) * 2004-03-31 2007-08-07 Brother Kogoy Kabushiki Kaisha Image forming apparatus
MXPA06011425A (es) * 2004-03-31 2007-03-12 Johnson & Johnson Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
WO2007014049A2 (fr) * 2005-07-22 2007-02-01 The Regents Of The University Of California Compositions d'heparine inhibitrices de la selectine
DK3219328T3 (da) 2005-12-29 2020-07-13 Janssen Biotech Inc Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
CA2648035A1 (fr) * 2006-03-31 2007-10-11 Centocor, Inc. Mimetiques de l'epo humaine a region centrale a charniere, compositions, procedes et utilisations dans la prevention ou le traitement de pathologies relatives a l'intolerance au glucose ou de l'anemie associee a une nephropathie
TW200843794A (en) * 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
US20100021538A1 (en) * 2008-02-29 2010-01-28 Youngro Byun Pharmaceutical compositions containing heparin derivatives
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
AU2009308935B2 (en) 2008-10-31 2015-02-26 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2396011B1 (fr) 2009-02-12 2016-04-13 Janssen Biotech, Inc. Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations
EP2582722A4 (fr) 2010-06-19 2013-12-18 Sloan Kettering Inst Cancer Anticorps contre gd2
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9693552B2 (en) 2012-02-21 2017-07-04 Advanced Bionutrition Corporation Compositions and methods for target delivering a bioactive agent to aquatic organisms
SG11201407340YA (en) 2012-05-09 2014-12-30 Cantex Pharmaceuticals Inc Treatment of myelosuppression
US20140255403A1 (en) 2013-03-06 2014-09-11 Hadasit Medical Research Services & Development Ltd. Oral composition comprising a tnf antagonist and use thereof
CA2903576C (fr) 2013-03-15 2021-06-08 Nai-Kong V. Cheung Anticorps anti-gd2 a haute affinite
BR112015023224B1 (pt) 2013-03-15 2021-03-30 Mannkind Corp Método para a síntese de um bis-3,6-aminoalquil-2,5- dicetopiperazina n-protegido a partir de um éster de amino ativo a-n-protegido cíclico
WO2016033549A2 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
WO2016033556A1 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
WO2016133910A1 (fr) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Traitement de cancers et de troubles de cellules souches hématopoïétiques privilégiés par interaction cxcl12-cxcr4
CN107667120B (zh) 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
BR112019000683A2 (pt) 2016-07-15 2019-04-24 Poseida Therapeutics Inc receptores de antígeno quiméricos e métodos para uso
WO2018014039A1 (fr) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Récepteurs d'antigènes chimériques (cars) spécifiques pour muc1 et leurs procédés d'utilisation
JP6409837B2 (ja) * 2016-09-08 2018-10-24 トヨタ自動車株式会社 回転電機ロータ及び回転電機ロータの製造方法
WO2018098501A1 (fr) 2016-11-28 2018-05-31 Lipocine Inc. Traitement oral à base d'undécanoate de testostérone
EP3574012A1 (fr) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Molécules bispécifiques de liaison à her2 et cd3
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
KR20190115042A (ko) 2017-02-07 2019-10-10 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US20210139557A1 (en) 2017-12-20 2021-05-13 Poseida Therapeutics, Inc. Vcar compositions and methods for use
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
JP2022513507A (ja) 2018-12-20 2022-02-08 ポセイダ セラピューティクス，インコーポレイティド ナノトランスポゾン組成物および使用方法
KR20210116540A (ko) 2019-01-15 2021-09-27 얀센 바이오테크 인코포레이티드 소아 특발성 관절염의 치료를 위한 항-tnf 항체 조성물 및 방법
CN113330031A (zh) 2019-01-23 2021-08-31 詹森生物科技公司 用于在治疗银屑病关节炎的方法中使用的抗tnf抗体组合物
EP3938391A1 (fr) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
CA3133388A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procedes de production de compositions d'anticorps anti-tnf
US20220153830A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
EP3972690A4 (fr) 2019-05-23 2023-07-05 Janssen Biotech, Inc. Méthode de traitement de maladie intestinale inflammatoire au moyen d'une polythérapie d'anticorps dirigés contre il -23 et tnf alpha
AU2020288404A1 (en) 2019-06-03 2022-02-03 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
EP3976648A1 (fr) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
WO2021028752A1 (fr) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anticorps anti-tfn pour le traitement du diabète de type i
JP2022547866A (ja) 2019-09-05 2022-11-16 ポセイダ セラピューティクス，インコーポレイティド 同種異系細胞組成物と使用方法
WO2021127505A1 (fr) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Compositions anti-muc1 et méthodes d'utilisation
AU2021230361A1 (en) 2020-03-04 2022-09-08 Poseida Therapeutics, Inc. Compositions and methods for the treatment of Metabolic Liver Disorders
WO2021183795A1 (fr) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Récepteurs stimulateurs chimériques et procédés d'utilisation dans l'activation et la différenciation de lymphocytes t
CN115996747A (zh) 2020-04-14 2023-04-21 波赛达治疗公司 用于治疗癌症的组合物和方法
WO2021214588A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections à coronavirus
WO2021214587A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections virales
EP4298205A1 (fr) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Cellules souches pluripotentes induites génétiquement modifiées et leurs procédés d'utilisation
EP4301863A1 (fr) 2021-03-04 2024-01-10 Poseida Therapeutics, Inc. Compositions et méthodes de traitement de l'hémophilie
AU2022306144A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023281463A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
CA3233506A1 (fr) 2021-10-04 2023-04-13 Joseph S. LUCAS Compositions de transposons et leurs procedes d'utilisation
WO2023164573A1 (fr) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Cellules modifiées et leurs procédés d'utilisation
WO2024036273A1 (fr) 2022-08-11 2024-02-15 Poseida Therapeutics, Inc. Compositions chimériques de corécepteurs cd8-alpha et procédés d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2055083A (en) * 1932-07-13 1936-09-22 Winthrop Chem Co Inc Pharmaceutical preparation
US3395222A (en) * 1966-03-11 1968-07-30 Armour Pharma Prolongation of clotting time of blood
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations

Also Published As

Publication number Publication date
JPS6055485B2 (ja) 1985-12-05
PL201666A1 (pl) 1979-04-09
JPS53133616A (en) 1978-11-21
FR2374910A1 (fr) 1978-07-21
AU519231B2 (en) 1981-11-19
DE2747378A1 (de) 1978-04-27
DK470277A (da) 1978-04-24
LU78361A1 (fr) 1979-06-01
IE45894L (en) 1978-04-23
AU2993777A (en) 1979-04-26
US4239754A (en) 1980-12-16
DD138881A5 (de) 1979-11-28
IE45894B1 (en) 1982-12-29
ES463427A1 (es) 1979-06-01
AR224100A1 (es) 1981-10-30
SE7711895L (sv) 1978-04-24
NL7711610A (nl) 1978-04-25

Similar Documents

Publication Publication Date Title
JPS5437220B2 (fr)
JPS5383816U (fr)
JPS52136333U (fr)
JPS5392532U (fr)
JPS5357019U (fr)
JPS5366341U (fr)
JPS536791U (fr)
CS177791B1 (fr)
CS176345B1 (fr)
JPS5383919U (fr)
BG23391A1 (fr)
BE851182A (fr)
CH605189A5 (fr)
CH604319A5 (fr)
CH602342A5 (fr)
CH601789A5 (fr)
CH599496A5 (fr)
CH598473A5 (fr)
CH597921A5 (fr)
DD125050A1 (fr)
CH594545A5 (fr)
CH591383A5 (fr)
BG23494A1 (fr)
DD125407A1 (fr)
BG23381A1 (fr)

Legal Events

Date Code Title Description
ST Notification of lapse